LQDA Liquidia Corporation

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.



Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at .



An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.



About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit 

Contact Information



Investors:

Jason Adair

Chief Business Officer

919.328.4350





Media:

Patrick Wallace

Director, Corporate Communications

919.328.4383



EN
28/05/2025

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcar...

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.Access to a webcast will be available to ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powde...

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effortDemonstrated tolerability and titratability in the pivotal INSPIRE studyLiquidia will host a webcast Tuesday, May 27, 2025 at 8:30 a.m. ET to provide an update on...

May 23, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Provides Update on Litigation Filed by United The...

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patentDoes not impact FDA’s ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company develop...

May 12, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports First Quarter 2025 Financial Results and ...

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a...

May 8, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Present at BofA Securities 2025 Health Care Co...

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company’s Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET ...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch